Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients

ABSTRACT Background The risk factors and clinical prediction of cardiovascular comorbidities in patients with breast cancer have not been fully clarified. Aims This retrospective case–control study was designed to investigate the factors affecting myocardial ischemia occurrence in breast cancer pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Yeyan Lei, Dongmei Li, Shuang Bai, Xing Zeng, Rongyuan Yang, Qing Liu
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Reports
Subjects:
Online Access:https://doi.org/10.1002/cnr2.70075
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849412355592552448
author Yeyan Lei
Dongmei Li
Shuang Bai
Xing Zeng
Rongyuan Yang
Qing Liu
author_facet Yeyan Lei
Dongmei Li
Shuang Bai
Xing Zeng
Rongyuan Yang
Qing Liu
author_sort Yeyan Lei
collection DOAJ
description ABSTRACT Background The risk factors and clinical prediction of cardiovascular comorbidities in patients with breast cancer have not been fully clarified. Aims This retrospective case–control study was designed to investigate the factors affecting myocardial ischemia occurrence in breast cancer patients. Methods and Results A total of 194 cases (144 breast cancer and 50 benign breast tumor patients) were included. Univariate and multivariable Cox regression found that ApoB, age, and HER2 were significant factors responsible for the myocardial ischemia occurrence in breast cancer patients. By comparing the significance of ApoB in breast cancer patients versus benign breast tumor patients, it was observed that ApoB and HER2 were crucial predictors of myocardial ischemia in breast cancer patients compared to those with benign breast tumors. These factors were utilized to construct the clinical prediction model, achieving a combined area under the curve (AUC) of 0.583. The decision curve analysis (DCA) indicated that the model‐predicted population, within a threshold ranging from 0.35 to 0.70, would experience a therapeutically clinical net benefit. Kaplan–Meier plot indicated that ApoBhigh and HER2+ categories were high‐risk populations for myocardial ischemia in breast cancer patients, although there was no significant difference between ApoBlow and ApoBhigh subgroups for the 3‐year disease‐free survival. Conclusion We demonstrated that ApoB and HER2 were potential factors in predicting the myocardial ischemia occurrence in breast cancer patients. This study will help provide clinical evidence for the early prediction of cardiovascular comorbidities in breast cancer patients.
format Article
id doaj-art-70e23dbda4244754a80e47adb152ea42
institution Kabale University
issn 2573-8348
language English
publishDate 2025-07-01
publisher Wiley
record_format Article
series Cancer Reports
spelling doaj-art-70e23dbda4244754a80e47adb152ea422025-08-20T03:34:28ZengWileyCancer Reports2573-83482025-07-0187n/an/a10.1002/cnr2.70075Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer PatientsYeyan Lei0Dongmei Li1Shuang Bai2Xing Zeng3Rongyuan Yang4Qing Liu5Zhuhai Doumen Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Chinese Medicine‐Zhuhai Hospital, the Second Clinical School of Medicine Guangzhou University of Chinese Medicine Zhuhai ChinaZhuhai Doumen Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Chinese Medicine‐Zhuhai Hospital, the Second Clinical School of Medicine Guangzhou University of Chinese Medicine Zhuhai ChinaZhuhai Doumen Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Chinese Medicine‐Zhuhai Hospital, the Second Clinical School of Medicine Guangzhou University of Chinese Medicine Zhuhai ChinaDepartment of Clinical Medicine The Third Clinical School of Guangzhou Medical University Guangzhou ChinaZhuhai Doumen Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Chinese Medicine‐Zhuhai Hospital, the Second Clinical School of Medicine Guangzhou University of Chinese Medicine Zhuhai ChinaZhuhai Doumen Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Chinese Medicine‐Zhuhai Hospital, the Second Clinical School of Medicine Guangzhou University of Chinese Medicine Zhuhai ChinaABSTRACT Background The risk factors and clinical prediction of cardiovascular comorbidities in patients with breast cancer have not been fully clarified. Aims This retrospective case–control study was designed to investigate the factors affecting myocardial ischemia occurrence in breast cancer patients. Methods and Results A total of 194 cases (144 breast cancer and 50 benign breast tumor patients) were included. Univariate and multivariable Cox regression found that ApoB, age, and HER2 were significant factors responsible for the myocardial ischemia occurrence in breast cancer patients. By comparing the significance of ApoB in breast cancer patients versus benign breast tumor patients, it was observed that ApoB and HER2 were crucial predictors of myocardial ischemia in breast cancer patients compared to those with benign breast tumors. These factors were utilized to construct the clinical prediction model, achieving a combined area under the curve (AUC) of 0.583. The decision curve analysis (DCA) indicated that the model‐predicted population, within a threshold ranging from 0.35 to 0.70, would experience a therapeutically clinical net benefit. Kaplan–Meier plot indicated that ApoBhigh and HER2+ categories were high‐risk populations for myocardial ischemia in breast cancer patients, although there was no significant difference between ApoBlow and ApoBhigh subgroups for the 3‐year disease‐free survival. Conclusion We demonstrated that ApoB and HER2 were potential factors in predicting the myocardial ischemia occurrence in breast cancer patients. This study will help provide clinical evidence for the early prediction of cardiovascular comorbidities in breast cancer patients.https://doi.org/10.1002/cnr2.70075ApoB and HER2breast cancercase–control studyclinical prediction modelmyocardial ischemia risk
spellingShingle Yeyan Lei
Dongmei Li
Shuang Bai
Xing Zeng
Rongyuan Yang
Qing Liu
Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
Cancer Reports
ApoB and HER2
breast cancer
case–control study
clinical prediction model
myocardial ischemia risk
title Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
title_full Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
title_fullStr Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
title_full_unstemmed Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
title_short Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
title_sort clinical relationship between serum apob her2 and myocardial ischemia risk in breast cancer patients
topic ApoB and HER2
breast cancer
case–control study
clinical prediction model
myocardial ischemia risk
url https://doi.org/10.1002/cnr2.70075
work_keys_str_mv AT yeyanlei clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients
AT dongmeili clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients
AT shuangbai clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients
AT xingzeng clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients
AT rongyuanyang clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients
AT qingliu clinicalrelationshipbetweenserumapobher2andmyocardialischemiariskinbreastcancerpatients